FDA approves novel preventive treatment for migraine
FDA approves Aimovig for the preventive treatment of migraine. Aimovig works by blocking the activity of a molecule that is involved in migraine attacks.
www.fda.gov
“In 2018, the FDA approved the first calcitonin gene-related peptide (CGRP) inhibitors. These new drugs are designed to prevent episodic migraine (up to 14 headache days per month), chronic migraine (15 headache days per month or more), and medication overuse headaches. CGRP inhibitors were the first class of drugs developed to prevent migraines with or without visual auras. Experts recommend their use for those with 6 or more migraine days per month, or when older preventive migraine treatments fail or are not tolerated by the migraine sufferer.
In 2021 a subset of CGRP inhibitors were approved to treat acute migraine.
The American Migraine Foundation calls CGRP inhibitors, ‘the biggest news in migraine treatment and prevention in decades.’”
From: Migraine: How CGRP Inhibitors Can Help
These can be used as preventative (prophylactic) and for the treatment of acute migraine attacks.
“Calcitonin gene receptor peptide (CGRP) antagonists
CGRP antagonists can be used for both acute migraine treatment as well as prophylactically.[14] CGRP is a neuropeptide which is thought to induce migraines via vasodilation of cranial arteries.[14] CGRP can also release inflammatory agents and cause nervous system sensitization.[14] It is theorized that by antagonizing the CGRP receptor of the trigeminal ganglia, lowered CGRP is released and less migraine occurs.[14] Erenumab is a highly selective human monoclonal antibody which is a promising new development in migraine treatment.[14] It has low risk of hepatoxicity like gepants can have, due to being mostly eliminated via proteolysis.[15]”
From: Antimigraine drug - Wikipedia
Also: Calcitonin gene-related peptide receptor antagonist - Wikipedia
CGRP Antagonists for Migraine: A Growing Drug Class
Calcitonin gene-related peptide (CGRP) monoclonal antibodies are one of the newer treatment options for the prevention of migraine, and the drug class is growing.
www.healthline.com
Rashid A, Manghi A. Calcitonin Gene-Related Peptide Receptor. [Updated 2022 Jul 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: Calcitonin Gene-Related Peptide Receptor - StatPearls - NCBI Bookshelf
Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, Viswanath O. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y. PMID: 30874961.
CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review - PubMed
Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. CGRP antagonists appear to significantly improve treatment...
pubmed.ncbi.nlm.nih.gov
This woman who is a migraine sufferer and has a background in biochemistry explains why she doesn’t take cgrp antagonists:
“Anti-CGRP medications can be an excellent option for the prevention of episodic or chronic migraine, but like all migraine medications, there are pros and cons. I wanted to discuss why I decided NOT to use CGRP antagonists as part of my migriane treatment. This is all just MY interpretation of the data that I found.This is not nearly all the data or information that there is, so make sure you do your own research and talk to your doctor about whether CGRP Antagonists are right for your migraine treatment. I'm not an expert, just a migraine patient!”
View: https://m.youtube.com/watch?v=NjcH_WoB334
Last edited: